JSPR250117P20000
- 13.40
- +0.60+4.69%
Jasper Therapeutics Newsroom
HC Wainwright & Co. Maintains Buy on Jasper Therapeutics, Lowers Price Target to $40
Jasper Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $40 to $80
RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Promising Efficacy and Safety of Jasper Therapeutics' Briquilimab Boosts Buy Rating
Crude Oil Down 1%; US Weekly Jobless Claims Decline
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
US Stocks Down; Acuity Brands Posts Weak Revenue
Jasper Therapeutics Shares Are Trading Lower. The Company Reported Preliminary Data From Its BEACON Phase 1b/2a Study.
Jasper Therapeutics Says Preliminary Study Data for Urticaria Treatment Show Reduced Disease Activity
Express News | Jasper Therapeutics Inc - Data Supports Commencement of Csu Registrational Program Expected to Commence Second Half of 2025
Express News | Jasper Therapeutics Inc - 66% Maintained Well Controlled Disease at 12 Weeks in 240Mg Cohort
BMO Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $63
Jasper Therapeutics to Host Webinar to Present Preliminary Data From the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Analysts Are Bullish on These Healthcare Stocks: Jasper Therapeutics (JSPR), Celldex (CLDX)
Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)
Jasper Launches AI Studio, Empowering Enterprise Marketing Teams to Build & Scale Generative AI Solutions
Jasper Therapeutics Initiated at Outperform by BMO Capital